Mark Baum has been the CEO of Harrow Health, Inc. (NASDAQ:HROW) since 2012. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. This method should give us information to assess how appropriately the company pays the CEO.
How Does Mark Baum's Compensation Compare With Similar Sized Companies?
At the time of writing, our data says that Harrow Health, Inc. has a market cap of US$177m, and reported total annual CEO compensation of US$1.1m for the year to December 2018. While we always look at total compensation first, we note that the salary component is less, at US$411k. We further remind readers that the CEO may face performance requirements to receive the non-salary part of the total compensation. We looked at a group of companies with market capitalizations from US$100m to US$400m, and the median CEO total compensation was US$1.1m.
So Mark Baum is paid around the average of the companies we looked at. While this data point isn't particularly informative alone, it gains more meaning when considered with business performance.
You can see a visual representation of the CEO compensation at Harrow Health, below.
Is Harrow Health, Inc. Growing?
On average over the last three years, Harrow Health, Inc. has grown earnings per share (EPS) by 104% each year (using a line of best fit). In the last year, its revenue is up 34%.
This shows that the company has improved itself over the last few years. Good news for shareholders. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. It could be important to check this free visual depiction of what analysts expect for the future.
Has Harrow Health, Inc. Been A Good Investment?
Most shareholders would probably be pleased with Harrow Health, Inc. for providing a total return of 197% over three years. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.
Mark Baum is paid around the same as most CEOs of similar size companies.
Shareholders would surely be happy to see that shareholder returns have been great, and the earnings per share are up. Although the pay is a normal amount, some shareholders probably consider it fair or modest, given the good performance of the stock. So you may want to check if insiders are buying Harrow Health shares with their own money (free access).
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.